BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 24614628)

  • 1. Difference in statin effects on neointimal coverage after implantation of drug-eluting stents.
    Yamamoto H; Ikuta S; Kobuke K; Yasuda M; Ikeda T; Yamaji K; Ueno M; Iwanaga Y; Miyazaki S
    Coron Artery Dis; 2014 Jun; 25(4):290-5. PubMed ID: 24614628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serial assessment of vessel interactions after drug-eluting stent implantation in unprotected distal left main coronary artery disease using frequency-domain optical coherence tomography.
    Fujino Y; Attizzani GF; Bezerra HG; Wang W; Tahara S; Yamamoto H; Chamie D; Kanaya T; Mehanna E; Takagi K; Nakamura S; Costa MA
    JACC Cardiovasc Interv; 2013 Oct; 6(10):1035-45. PubMed ID: 24156964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of long-term follow-up with neointimal coverage and stent apposition after sirolimus-eluting stent implantation by optical coherence tomography.
    Li S; Gai L; Yang T; Zhang L; Xu X; Bai Q; Xu H; Wang Y
    Catheter Cardiovasc Interv; 2013 Apr; 81(5):768-75. PubMed ID: 22639418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of High-Dose Statin Therapy on Drug-Eluting Stent Strut Coverage.
    Kim JS; Kim JH; Shin DH; Kim BK; Ko YG; Choi D; Jang Y; Hong MK
    Arterioscler Thromb Vasc Biol; 2015 Nov; 35(11):2460-7. PubMed ID: 26359512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Initial findings of impact of strut width on stent coverage and apposition of sirolimus-eluting stents assessed by optical coherence tomography.
    Nakatani S; Nishino M; Taniike M; Makino N; Kato H; Egami Y; Shutta R; Tanouchi J; Yamada Y
    Catheter Cardiovasc Interv; 2013 Apr; 81(5):776-81. PubMed ID: 22517601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Statins and prevention of stent-related late adverse events.
    Uemura S
    Coron Artery Dis; 2014 Jun; 25(4):277-8. PubMed ID: 24710353
    [No Abstract]   [Full Text] [Related]  

  • 7. Quantitative and qualitative changes in DES-related neointimal tissue based on serial OCT.
    Kim JS; Hong MK; Shin DH; Kim BK; Ko YG; Choi D; Jang Y
    JACC Cardiovasc Imaging; 2012 Nov; 5(11):1147-55. PubMed ID: 23153915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Very early tissue coverage after drug-eluting stent implantation: an optical coherence tomography study.
    Takahara M; Kitahara H; Nishi T; Miura K; Miyayama T; Sugimoto K; Nakayama T; Fujimoto Y; Kobayashi Y
    Int J Cardiovasc Imaging; 2017 Jan; 33(1):25-30. PubMed ID: 27601229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).
    Ormiston J; Webster M; Stewart J; Vrolix M; Whitbourn R; Donohoe D; Knape C; Lansky A; Attizzani GF; Fitzgerald P; Kandzari DE; Wijns W
    JACC Cardiovasc Interv; 2013 Oct; 6(10):1026-34. PubMed ID: 24055443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tissue coverage of paclitaxel and sirolimus eluting stents in long term follow-up: optical coherence tomography study.
    Kochman J; Pietrasik A; Rdzanek A; Ścibisz A; Pawlak M; Filipiak KJ; Opolski G
    Cardiol J; 2013; 20(3):247-53. PubMed ID: 23788298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two-week interval optical coherence tomography: imaging evidence on neointimal coverage completion after implantation of the Endeavor zotarolimus-eluting stent.
    Nishinari M; Shimohama T; Tojo T; Shiono T; Shinagawa H; Kameda R; Aoyama N; Izumi T
    Catheter Cardiovasc Interv; 2013 Dec; 82(7):E871-8. PubMed ID: 23873677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. One-year head to head comparison of the neointimal response between sirolimus eluting stent with reservoir technology and everolimus eluting stent: an optical coherence tomography study.
    Shiratori Y; Brugaletta S; Alvarez-Contreras L; Azpeitia Y; Ospino N; Gaido S; Delahanty A; Santos A; Martin-Yuste V; Masotti M; Serruys PW; Windecker S; Sabaté M
    Catheter Cardiovasc Interv; 2013 Oct; 82(4):E428-36. PubMed ID: 23441068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early vascular healing with rapid breakdown biodegradable polymer sirolimus-eluting versus durable polymer everolimus-eluting stents assessed by optical coherence tomography.
    Tada T; Byrne RA; Schuster T; Cuni R; Kitabata H; Tiroch K; Dirninger A; Gratze F; Kaspar K; Zenker G; Joner M; Schömig A; Kastrati A
    Cardiovasc Revasc Med; 2013; 14(2):84-9. PubMed ID: 23352095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neointimal coverage on drug-eluting stent struts crossing side-branch vessels using optical coherence tomography.
    Her AY; Lee BK; Shim JM; Kim JS; Kim BK; Ko YG; Choi D; Jang Y; Hong MK
    Am J Cardiol; 2010 Jun; 105(11):1565-9. PubMed ID: 20494663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Head-to-head comparison of the neointimal response between metallic and bioresorbable everolimus-eluting scaffolds using optical coherence tomography.
    Gomez-Lara J; Brugaletta S; Farooq V; Onuma Y; Diletti R; Windecker S; Thuesen L; McClean D; Koolen J; Whitbourn R; Dudek D; Smits PC; Chevalier B; Regar E; Veldhof S; Rapoza R; Ormiston JA; Garcia-Garcia HM; Serruys PW
    JACC Cardiovasc Interv; 2011 Dec; 4(12):1271-80. PubMed ID: 22192368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optical coherence tomography assessment of in vivo vascular response after implantation of overlapping bare-metal and drug-eluting stents.
    Guagliumi G; Musumeci G; Sirbu V; Bezerra HG; Suzuki N; Fiocca L; Matiashvili A; Lortkipanidze N; Trivisonno A; Valsecchi O; Biondi-Zoccai G; Costa MA;
    JACC Cardiovasc Interv; 2010 May; 3(5):531-9. PubMed ID: 20488410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of early strut coverage between zotarolimus- and everolimus-eluting stents using optical coherence tomography.
    Kim S; Kim JS; Shin DH; Kim BK; Ko YG; Choi D; Cho YK; Nam CW; Hur SH; Jang Y; Hong MK
    Am J Cardiol; 2013 Jan; 111(1):1-5. PubMed ID: 23040589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation in 3 months duration of neointimal coverage after zotarolimus-eluting stent implantation by optical coherence tomography: the ENDEAVOR OCT trial.
    Kim JS; Jang IK; Fan C; Kim TH; Kim JS; Park SM; Choi EY; Lee SH; Ko YG; Choi D; Hong MK; Jang Y
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1240-7. PubMed ID: 20129551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Different patterns of vascular response between patients with or without diabetes mellitus after drug-eluting stent implantation: optical coherence tomographic analysis.
    Tanaka N; Terashima M; Rathore S; Itoh T; Habara M; Nasu K; Kimura M; Itoh T; Kinoshita Y; Ehara M; Tsuchikane E; Asakura K; Asakura Y; Katoh O; Suzuki T
    JACC Cardiovasc Interv; 2010 Oct; 3(10):1074-9. PubMed ID: 20965467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thin-cap fibroatheroma and large calcification at the proximal stent edge correlate with a high proportion of uncovered stent struts in the chronic phase.
    Ueda T; Uemura S; Watanabe M; Dote Y; Goryo Y; Sugawara Y; Soeda T; Okayama S; Kawata H; Kawakami R; Okura H; Saito Y
    Coron Artery Dis; 2016 Aug; 27(5):376-84. PubMed ID: 27164267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.